Federico Chinni, Managing Director- UCB Italy

Federico Chinni UCB Italy's Managing Director, Federico Chinni offeres his insights into UCB's positioning and its new product launches, the first for the company in ten years. He also weighs in on Italy's national Recovery and Resilience Plan and explains how the company was ready for digitalisation even before the pandemic. 
Our expectations for 2022 are mainly related to the launches of our products, including a drug for epilepsy and another for psoriasis; it is a year of great possibilities.
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report